# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-24-014745
Filing Date
2024-04-16
Accepted
2024-04-16 08:30:15
Documents
5
Period of Report
2024-04-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formdef14a.htm | DEF 14A | 579726
2 |  | formdef14a_001.jpg | GRAPHIC | 135928
3 |  | formdef14a_002.jpg | GRAPHIC | 114393
4 |  | proxy_001.jpg | GRAPHIC | 249163
5 |  | proxy_002.jpg | GRAPHIC | 244377
| Complete submission text file | 0001493152-24-014745.txt |  | 1605826

Mailing Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103 239-302-1707
Enveric Biosciences, Inc. (Filer) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38286 | Film No.: 24846167
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)